Promoter-bound METTL 3 maintains myeloid leukaemia 2 via m 6 A-dependent translation control 3 4 5

4 5 Isaia Barbieri, Konstantinos Tzelepis, Luca Pandolfini, Junwei Shi, Gonzalo Millán6 Zambrano, Samuel C. Robson1¶, Demetrios Aspris, Valentina Migliori, Andrew J. 7 Bannister, Namshik Han, Etienne De Braekeleer, Hannes Ponstingl, Alan Hendrick, 8 Christopher R. Vakoc, George S. Vassiliou & Tony Kouzarides. 9 10 The Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, 11 Cambridge, CB2 1QN, UK. 12 2 Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, CB10 1SA, UK. 13 3 Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA. 14 4 Storm Therapeutics Ltd, Moneta building (B280), Babraham Research Campus, Cambridge CB22 3AT, UK. 15 16 ♯ Present address: Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman 17 School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, 18 USA. 19 Present address: School of Pharmacy & Biomedical Science, St Michael's Building, University of 20 Portsmouth, White Swan Road, Portsmouth, UK" 21 *These authors contributed equally to the work. 22 Corresponding authors (t.kouzarides@gurdon.cam.ac.uk; gsv20@sanger.ac.uk) 23 24 25 26 Abstract 27 28 N6-methyladenosine (m6A) is an abundant internal RNA modification in both coding and 29